Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China

Abstract The combination of venetoclax (VEN) and azacitidine (AZA) has transformed the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive therapy. Nevertheless, real-world evidence on long-term outcomes in patients with AML treated with VEN + AZA remains limited. A retros...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Xuexing Chen, Qiong Yan, Chunfang Li, Fei Liu, Shaojun Guo, Juan Zhao, Yan Liang, Haiyan Wang, Weiming Li, Guolin Yuan
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Nature Portfolio 2026-04-01
Reeks:	Scientific Reports
Onderwerpen:	Venetoclax Acute myeloid leukemia Long-term treatment Efficacy Prognostic factors
Online toegang:	https://doi.org/10.1038/s41598-026-50426-0
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!